Da-Peng Dai (Dapeng Dai)

Years Active: 2020-2023
Publications (10 Years): 5

This page only lists publications with an associated author ORCID identifier.

Publications

Shuanghu Wang, Mengming Xia, Yu Wang, Zebei Lu, Peiwu Geng, Da-Peng Dai, Yunfang Zhou, Qingjun Wu
Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC-MS/MS. Thoracic cancer (2023)
Qingjun Wu, Yuying Qi, Shuanghu Wang, Jian Liu, Peiwu Geng, Quan Zhou, Wenqian Zhang, Jianping Cai, Bin Hu, Da-Peng Dai, Hui Li
Polymorphic mutations in the polb gene promoter and their impact on transcriptional activity. Thoracic cancer 13 (6) (2022)
Jian Liu, Hao Chen, Shuang-Hu Wang, Quan Zhou, Pei-Wu Geng, Yun-Fang Zhou, Hua-Lan Wu, Hai-Feng Shi, Fang Wang, Jie-Fu Yang, Jian-Ping Cai, Da-Peng Dai
Functional characterization of the defective CYP2C9 variant CYP2C9*18. Pharmacology research & perspectives 9 (1) (2021)
Qingjun Wu, Shan Zhou, Jian Liu, Hongfeng Tong, Yaoguang Sun, Wenxin Tian, Hanbo Yu, Chuan Huang, Donghang Li, Peng Jiao, Chao Ma, Jianping Cai, Da-Peng Dai
Two polymorphic mutations in promoter region of DNA polymerase β in relatively higher percentage of thymic hyperplasia patients. Thoracic cancer 12 (5) (2020)
Dongxu Wang, Da-Peng Dai, Hualan Wu, Jia Chong, You Lü, Ruoyun Yin, Xinlong Zhao, Anxu Zhao, Jiefu Yang, Hao Chen
Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation. Pharmacogenomics 21 (14) (2020)

Da-Peng Dai.css-eqlu8i{font-size:small;padding-left:4px;} (Dapeng Dai)